{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T22:49:00Z","timestamp":1648507740375},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.beha.2009.12.001","type":"journal-article","created":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T09:10:54Z","timestamp":1277370654000},"page":"109-119","source":"Crossref","is-referenced-by-count":2,"title":["Stem cell transplantation in chronic lymphocytic leukaemia \u2013 steering a safe course over shifting sands"],"prefix":"10.1016","volume":"23","author":[{"given":"Simon","family":"Hallam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2009.12.001_bib1","first-page":"1432","article-title":"Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL","author":"Johnson","year":"1996","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.beha.2009.12.001_bib2","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2009.12.001_bib3","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2009.12.001_bib4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2009.12.001_bib5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","article-title":"Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997","volume":"25","author":"Grever","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9583","key":"10.1016\/j.beha.2009.12.001_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.beha.2009.12.001_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2009.12.001_bib8","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2009.12.001_bib9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2009.12.001_bib10","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/1042819021000006547","article-title":"Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia","volume":"43","author":"Keating","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.beha.2009.12.001_bib11","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2009.12.001_bib12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2009.12.001_bib13","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2009.12.001_bib14","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood.V99.6.2245","article-title":"Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia","volume":"99","author":"Kennedy","year":"2002","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.beha.2009.12.001_bib15","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2005.01.9950","article-title":"Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial","volume":"23","author":"Elter","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2009.12.001_bib16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission\u2013experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"18","author":"Wendtner","year":"2004","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2009.12.001_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.leu.2403190","article-title":"Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H","volume":"18","author":"Montillo","year":"2004","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2009.12.001_bib18","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1182\/blood-2003-05-1549","article-title":"The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status","volume":"103","author":"Dreger","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.12.001_bib19","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V82.4.1366.1366","article-title":"Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia","volume":"82","author":"Rabinowe","year":"1993","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.12.001_bib20","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.1994.12.4.748","article-title":"Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results","volume":"12","author":"Khouri","year":"1994","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2009.12.001_bib21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/sj.bmt.1700730","article-title":"Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield","volume":"19","author":"Itala","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.beha.2009.12.001_bib22","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/bjc.1998.381","article-title":"Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?","volume":"77","author":"Dreger","year":"1998","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.beha.2009.12.001_bib23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1023\/A:1008474526373","article-title":"High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"9","author":"Pavletic","year":"1998","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.beha.2009.12.001_bib24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2004-01-0298","article-title":"Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses","volume":"105","author":"Milligan","year":"2005","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2009.12.001_bib25","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2009.12.001_bib26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.bmt.1705375","article-title":"Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience","volume":"37","author":"Jantunen","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.beha.2009.12.001_bib27","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1182\/blood-2002-06-1744","article-title":"Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia","volume":"101","author":"Ritgen","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.12.001_bib28","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2003-12-4321","article-title":"Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR","volume":"104","author":"Ritgen","year":"2004","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2009.12.001_bib29","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2005.04.531","article-title":"Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia","volume":"23","author":"Moreno","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2009.12.001_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0609.1998.tb01055.x","article-title":"Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy","volume":"61","author":"Sala","year":"1998","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2009.12.001_bib31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2141.2000.01900.x","volume":"108","author":"Michallet","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2009.12.001_bib32","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.leu.2402530","article-title":"Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia","volume":"16","author":"Dreger","year":"2002","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2009.12.001_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V98.1.29","article-title":"Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy","volume":"98","author":"Rawstron","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2009.12.001_bib34","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.V88.6.2228.bloodjournal8862228","article-title":"Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation","volume":"88","author":"Provan","year":"1996","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2009.12.001_bib35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bmt.1702026","article-title":"Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study","volume":"24","author":"Schey","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2009.12.001_bib36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s001090050349","article-title":"Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia","volume":"77","author":"Schultze","year":"1999","journal-title":"J Mol Med"},{"issue":"6","key":"10.1016\/j.beha.2009.12.001_bib37","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2006-04-007898","article-title":"Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia","volume":"108","author":"Zenz","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2009.12.001_bib38","first-page":"201","article-title":"Graft versus host disease in autologous stem cell transplantation","volume":"18","author":"Marin","year":"1999","journal-title":"J Exp Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.beha.2009.12.001_bib39","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1200\/JCO.2005.04.6037","article-title":"Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia","volume":"24","author":"Montillo","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2009.12.001_bib40","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.leu.2401201","article-title":"Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia","volume":"12","author":"Sutton","year":"1998","journal-title":"Leukemia"},{"issue":"5\u20136","key":"10.1016\/j.beha.2009.12.001_bib41","first-page":"467","article-title":"Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: report from the European Cooperative Group for bone marrow transplantation (8 cases)","volume":"30","author":"Michallet","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"issue":"3","key":"10.1016\/j.beha.2009.12.001_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","article-title":"HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry","volume":"124","author":"Michallet","year":"1996","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.beha.2009.12.001_bib43","doi-asserted-by":"crossref","first-page":"780","DOI":"10.7326\/0003-4819-125-9-199611010-00026","article-title":"Allogenic bone marrow transplantation in chronic lymphocytic leukemia","volume":"125","author":"Khouri","year":"1996","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.beha.2009.12.001_bib44","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.bmt.1702237","article-title":"Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia","volume":"25","author":"Pavletic","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.beha.2009.12.001_bib45","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/sj.bmt.1703548","article-title":"Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia","volume":"29","author":"Doney","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2009.12.001_bib46","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bmt.1705130","article-title":"Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease","volume":"36","author":"Toze","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2009.12.001_bib47","first-page":"669","article-title":"Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia","volume":"18","author":"Rondon","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2009.12.001_bib48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1700850","article-title":"Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia","volume":"20","author":"deMagalhaes-Silverman","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"10.1016\/j.beha.2009.12.001_bib49","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1200\/JCO.2005.03.962","article-title":"Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research","volume":"23","author":"Pavletic","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2009.12.001_bib50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1365-2141.1997.272673.x","article-title":"Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease","volume":"97","author":"Khouri","year":"1997","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2009.12.001_bib51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.leu.2402036","article-title":"Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status","volume":"15","author":"Esteve","year":"2001","journal-title":"Leukemia"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2009.12.001_bib52","first-page":"S47","article-title":"Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia","volume":"81","author":"Schetelig","year":"2002","journal-title":"Ann Hematol"},{"issue":"14","key":"10.1016\/j.beha.2009.12.001_bib53","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group","volume":"21","author":"Schetelig","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2009.12.001_bib54","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.beha.2009.12.001_bib55","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","article-title":"Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality","volume":"98","author":"Khouri","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2009.12.001_bib56","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2402905","article-title":"Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning","volume":"17","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.beha.2009.12.001_bib57","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","article-title":"Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia","volume":"23","author":"Sorror","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2009.12.001_bib58","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2006.06.004","article-title":"Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia","volume":"12","author":"Brown","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2009.12.001_bib59","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.leu.2403745","article-title":"Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis","volume":"19","author":"Dreger","year":"2005","journal-title":"Leukemia"},{"issue":"30","key":"10.1016\/j.beha.2009.12.001_bib60","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2009.12.001_bib61","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.bmt.1705357","article-title":"Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders","volume":"37","author":"Hertzberg","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"10.1016\/j.beha.2009.12.001_bib62","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1158\/1078-0432.CCR-05-0941","article-title":"Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)","volume":"11","author":"Caballero","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"7","key":"10.1016\/j.beha.2009.12.001_bib63","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","article-title":"In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation","volume":"96","author":"Kottaridis","year":"2000","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2009.12.001_bib64","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.12.001_bib65","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2005-08-3372","article-title":"Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study","volume":"107","author":"Delgado","year":"2006","journal-title":"Blood"},{"issue":"9487","key":"10.1016\/j.beha.2009.12.001_bib66","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(05)66996-6","article-title":"Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial","volume":"366","author":"Wagner","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.beha.2009.12.001_bib67","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbmt.2008.09.001","article-title":"The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia","volume":"14","author":"Delgado","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2009.12.001_bib68","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","article-title":"Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders","volume":"100","author":"Perez-Simon","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.12.001_bib69","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2007.06591.x","article-title":"Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia","volume":"137","author":"Khouri","year":"2007","journal-title":"Br J Haematol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609001029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609001029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T03:06:38Z","timestamp":1591412798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609001029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1521692609001029"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.12.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}